Studies have showed that ANRIL mediates EMT by regulating downstream gene/protein in cancers, such as pancreatic cancer, laryngeal squamous cell carcinoma and renal cell carcinoma [30–32]. This evidence concerns the gene CDKN2B-AS1 and hereditary clear cell renal cell carcinoma.